foxo4-dri senolytic peptide human trial 2024 2025 Frontiers Senolytic Interventions for Type 2
Senolytic Interventions for Type 2 Diabetes: Current Evidence and Future Directions FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway PMC Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry CHK2 USP37 axis stabilizes FOXO4 to sustain senescence and evade apoptosis PNAS
Pay in 4 interest-free payments of $6.49 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6




